Keith Crandell - Apr 2, 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Role
10%+ Owner
Signature
/s/ Keith Crandell, By: Mark McDonnell, attorney in-fact
Stock symbol
BOLD
Transactions as of
Apr 2, 2024
Transactions value $
$3,200,000
Form type
4
Date filed
4/4/2024, 04:30 PM
Previous filing
Mar 27, 2024
Next filing
Jun 14, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BOLD Common Stock Conversion of derivative security +590K +2156.36% 617K Apr 2, 2024 See footnotes F1, F2, F4
transaction BOLD Common Stock Conversion of derivative security +788K +1919.67% 829K Apr 2, 2024 See footnotes F1, F3, F4
transaction BOLD Common Stock Conversion of derivative security +1.05M 1.05M Apr 2, 2024 See footnotes F1, F5, F6
transaction BOLD Common Stock Purchase $1.07M +66.7K +10.8% $16.00* 684K Apr 2, 2024 See footnotes F2, F4, F7
transaction BOLD Common Stock Purchase $2.13M +133K +12.72% $16.00* 1.18M Apr 2, 2024 See footnotes F5, F6, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLD Series A Convertible Preferred Stock Conversion of derivative security -425K -100% 0 Apr 2, 2024 Common Stock 425K See footnotes F1, F2, F4
transaction BOLD Series A Convertible Preferred Stock Conversion of derivative security -586K -100% 0 Apr 2, 2024 Common Stock 586K See footnotes F1, F3, F4
transaction BOLD Series A Convertible Preferred Stock Conversion of derivative security -454K -100% 0 Apr 2, 2024 Common Stock 454K See footnotes F1, F5, F6
transaction BOLD Series B Convertible Preferred Stock Conversion of derivative security -228K -100% 0 Apr 2, 2024 Common Stock 228K See footnotes F1, F5, F6
transaction BOLD Series C Convertible Preferred Stock Conversion of derivative security -165K -100% 0 Apr 2, 2024 Common Stock 165K See footnotes F1, F2, F4
transaction BOLD Series C Convertible Preferred Stock Conversion of derivative security -201K -100% 0 Apr 2, 2024 Common Stock 201K See footnotes F1, F3, F4
transaction BOLD Series C Convertible Preferred Stock Conversion of derivative security -366K -100% 0 Apr 2, 2024 Common Stock 366K See footnotes F1, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
F2 Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F3 Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
F4 ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein, if any.
F5 Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F6 ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
F7 Reflects shares purchased by ARCH IX in the Issuer's initial public offering.
F8 Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering.

Remarks:

This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH IX, AVP IX LP, ARCH IX Overage, AVP IX Overage LP, AVP IX LLC, ARCH X Overage, AVP X Overage LP, AVP X LLC, Robert Nelsen, Keith Crandell, Steve Gillis and Clint Bybee (collectively, the "Reporting Persons"). Kristina Burow is filing her own Form 4 separately.